NCT01892189View on ClinicalTrials.gov

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Ketamine-Induced Brain Activity ChangesPsychotic-like Symptoms
Interventions
DRUG

Ketamine

Ketamine intravenous administration.

DRUG

TAK-063

TAK-063 tablets

DRUG

TAK-063 Placebo

TAK-063 placebo-matching tablets

Trial Locations (1)

84108

The Brain Institute, University of Utah, Salt Lake City

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01892189 - Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults | Biotech Hunter | Biotech Hunter